Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.

Schepens Eye Research Institute, Harvard Medical School, 20 Staniford Street, Boston, MA 02114, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 08/2006; 103(30):11405-10. DOI: 10.1073/pnas.0506112103
Source: PubMed

ABSTRACT Transparency of the cornea, the window of the eye, is a prerequisite for vision. Angiogenesis into the normally avascular cornea is incompatible with good vision and, therefore, the cornea is one of the few tissues in the human body where avascularity is actively maintained. Here, we provide evidence for a critical mechanism contributing to corneal avascularity. VEGF receptor 3, normally present on lymphatic and proliferating blood vascular endothelium, is strongly constitutively expressed by corneal epithelium and is mechanistically responsible for suppressing inflammatory corneal angiogenesis.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose:To analyzed the effect of an RvD1 analogue (RvD1a) on dendritic cell maturation, T cell sensitization, and allograft rejection in corneal allotransplantation. Methods:RvD1 receptor expression (ALX/FPR2) on bone marrow-derived dendritic cells (BMDC) was measured using quantitative Real-Time PCR. We determined BMDC maturation after treatment with RvD1a using ELISA to measure IL-12 protein expression and flow cytometry to assess the expression of CD40, MHC II, CD80, and CD86. After corneal transplantation in BALB/c mice we analyzed T cell infiltration in the cornea and the draining lymph nodes using flow cytometry. The ELISPOT assay was used to measure T cell sensitization via the direct and indirect pathway. Angiogenesis and lymphangiogenesis in the cornea after transplantation were measured using immunohistochemistry. Graft opacity and survival were evaluated by slit lamp biomicroscopy. Results:The RvD1 receptor, ALX/FPR2, was expressed at a significantly lower level on immature than mature DCs, and RvD1a reduced DC expression of MHC II, CD40 and IL-12 following LPS stimulation. Using a murine model of corneal transplantation RvD1a-treated hosts exhibited significantly reduced allosensitization as demonstrated by decreased frequencies of IFN-γ-secreting T cells in the draining lymph nodes, and reduced T cell infiltration into the grafts. Graft survival was significantly enhanced and angiogenesis at the graft site was suppressed in RvD1a-treated compared to vehicle-treated hosts. Conclusions:These results suggest that RvD1 inhibits DC maturation and reduces alloimmune sensitization following transplantation, thereby establishing a novel connection between resolvin D1 and the regulation of DC-mediated antigen-specific immunity.
    Investigative ophthalmology & visual science 08/2014; DOI:10.1167/iovs.14-14356 · 3.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the effect of VEGF-C and VEGF-D blockade via soluble VEGFR-3 (sVEGFR-3) on T cell allosensitization, corneal neovascularization, and transplant survival. Corneal intrastromal suture placement and allogeneic transplantation were performed on BALB/c mice to evaluate the effect of sVEGFR-3 on corneal neovascularization. Soluble VEGFR-3 trap was injected intraperitoneally to block VEGF-C/D (every other day starting the day of surgery). Immunohistochemical staining of corneal whole mounts was performed using anti-CD31 (PECAM-1) and anti-LYVE-1 antibodies to quantify the levels of hem- and lymphangiogenesis, respectively. Mixed lymphocyte reaction (MLR) was performed to assess indirect and direct host T cell allosensitization and the frequencies of IFN-gamma-producing T cells in the draining lymph nodes were assessed using flow cytometry. Graft opacity and survival was evaluated by slit-lamp biomicroscopy. Treatment with sVEGFR-3 resulted in a significant blockade of lymphangiogenesis 2 weeks post-transplantation and significantly prolonged corneal allograft survival compared to the control group at 8 weeks post-transplantation (87.5 % vs. 50 %), and this was associated with significant reduction in the frequencies of allosensitized T cells and decreased frequencies of IFN-gamma-producing CD4 T cells. Soluble VEGFR-3 suppresses corneal lymphangiogenesis and allograft rejection and may offer a viable therapeutic modality for corneal neovascularization and corneal transplantation.
    Albrecht von Graæes Archiv für Ophthalmologie 08/2014; 252(11). DOI:10.1007/s00417-014-2749-5 · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The adult sclera is free of lymphatic vessels, but contains a net of blood vessels. Whether and when this selectively lymphangiogenic privilege is achieved during embryologic development is not known yet. Therefore, we investigated the developing human sclera for blood- and lymphatic vessels in 34 abortions/stillborns (12-38 weeks of gestation). The probes were subdivided into three groups (group 1: 12-18 weeks of gestation, n=10; group 2: 19-23 weeks of gestation, n=13; group 3: 24-38 weeks of gestation, n=11), and prepared for paraffin sections followed by immunohistochemistry against CD31 to detect blood vessels, and against lymphatic vessel endothelial hyaluronan receptor-1 (LYVE1)/podoplanin to detect lymphatic vessels. We could show, that in the human episclera distinct CD31+ blood vessels are present as early as week of gestation 13. Their amount increased during pregnancy, whereas stromal CD31+ blood vessels were elevated in early pregnancy and regressed with ongoing pregnancy. In the lamina fusca CD31+ blood vessels were absent at any time point investigated. Single LYVE1+ cells were identified primarily in the episclera; their amount decreased significantly with increasing gestational ages (group 1 compared to group 3: p<0.01). However, LYVE1+/podoplanin+ lymphatic vessels were not detectable in the sclera at any gestational ages analyzed. In contrast to the conjunctiva where LYVE1+ /podoplanin+ lymphatic vessels were detectable as early as week 17, the amount of LYVE1+ cells in the sclera was highest in early pregnancy (group 1), with a significant decrease during continuing pregnancy (p<0.001). These findings are the first evidence for a fetal lymphangiogenic privilege of the sclera and show, that the fetal human sclera contains CD31+ blood vessels, but is primarily alymphatic. Our findings suggest a strong expression of selectively antilymphangiogenic factors, making the developing sclera a potential model to discern antilymphangiogenic mechanisms.
    Experimental Eye Research 06/2014; 125. DOI:10.1016/j.exer.2014.06.010 · 3.02 Impact Factor

Full-text (2 Sources)

Available from
May 27, 2014